The original success of Viagra undeniably reshaped the pharmaceutical landscape, but investing in companies primarily reliant on generic versions presents a complex picture. While early returns were impressive, the end of patents and the emergence of less expensive alternatives have weakened sales. Consequently, a thorough analysis of ongoing reven